{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:36:22Z","timestamp":1787798182450,"version":"build-2784847793"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jtha.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T11:55:57Z","timestamp":1673870157000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021"],"prefix":"10.1016","volume":"21","author":[{"given":"Maria","family":"Abbattista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ciavarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.01.010_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators","volume":"59","author":"Soucie","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.01.010_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.010_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.010_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.010_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A\u00a0randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.010_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.010_bib7","first-page":"141","article-title":"Extended half-life (EHL) coagulation factors: a new era in the management of haemophilia patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turk J Hematol"},{"key":"10.1016\/j.jtha.2023.01.010_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13641","article-title":"Emicizumab: Review of the literature and critical appraisal","volume":"25","author":"Rodriguez-Merchan","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.010_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2023.01.010_bib10","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1111\/hae.14110","article-title":"Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study","volume":"26","author":"Khoo","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.010_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.010_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.010_bib13","first-page":"35","article-title":"Switching toward the use of recombinant factor VIII Fc fusion protein study among 30 patients with severe hemophilia A","volume":"78","author":"Sattler","year":"2020","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1016\/j.jtha.2023.01.010_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.010_bib15","first-page":"29","article-title":"Real-world safety of emicizumab: the first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database","volume":"136","author":"Shang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.010_bib16","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies","volume":"138","author":"Howard","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:06Z","timestamp":1761536286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1538783623000387"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.010","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}